Mucopolysaccharidosis IVB and sensorineural deafness associated with the CDH23 gene: A unique clinical case

Abstract

BACKROUND: Mucopolysaccharidoses are a group of lysosomal storage diseases belonging to orphan diseases. Certain types of mucopolysaccharides have a typical musculoskeletal findings and radiological changes. The mucopolysaccharidosis IVB is a rare type. Thus, >95% of cases of the mucopolysaccharidosis IV are subtype A.

CLINICAL CASE: Сlinical and radiological changes and genetic examination were performed to a 9-year-old patient with sensorineural deafness who applied to a medical institution with complaints of right hip pain and limping.

DISCUSSION: Based on complaints and radiological changes of the hip joints, the patient was initially diagnosed with Legg–Calve–Perthes disease. The presence of a symmetrical bilateral process, pathognomonic changes in the acetabulum and femoral heads, and an atypical clinic of Legg–Calve–Perthes disease made us suspect mucopolysaccharidos. Enzymatic analysis revealed a significant decrease in the beta-D-galactosidase enzyme activity. In addition, two compound heterozygous variants in the GLB1 gene were identified: the pathogenic variant c.808T>G, inherited from the father, and an insertion of a mobile genetic element, inherited from the mother. Only one variant in the GLB1 gene was detected in the brother (born in 2009), and none of the above GLB1 variants was detected in the older brother (born in 2003). Moreover, the proband (with clinical mucopolysaccharidos IVB) and his brother (born in 2009) (without mucopolysaccharidos IVB) inherited pathogenic CDH23 variants (c.6992T>C and c.805C>T) from their mother and father, respectively, which is consistent with their having sensorineural hearing loss.

CONCLUSIONS: The uniqueness of this clinical case is the presence of the rare type of mucopolysaccharidos and the separate genetic cause of sensorineural hearing loss in a single patient. The diagnosis of mucopolysaccharidos IVB in the proband was confirmed by biochemical and molecular genetic tests, and the diagnosis of CDH23-associated sensorineural deafness in the proband and brother (born in 2009) was confirmed by molecular genetic testing.

Keywords

mucopolysaccharidosis IVB / orthopedics / dysostosis multiplex / hearing loss / Legg–Calve–Perthes disease / genetics

References

[1] Wraith JE, Rogers JG, Danks DM. The mucopolysaccharidoses. J Paediatr Child Health. 1987;23:329–334. DOI: 10.1111/j.1440-1754.1987.tb00284.x

[2] Wraith J.E., Rogers J.G., Danks D.M. The mucopolysaccharidoses // J. Paediatr. Child. Health. 1987. Vol. 23. P. 329–334. DOI: 10.1111/j.1440-1754.1987.tb00284.x

[3] Demydchuk M, Hill CH, Zhou A, et al. Insights into Hunter syndrome from the structure of iduronate-2-sulfatase. Nat Commun. 2017;8(1). DOI: 10.1038/ncomms15786

[4] Demydchuk M., Hill C.H., Zhou A. et al. Insights into Hunter syndrome from the structure of iduronate-2-sulfatase // Nat. Commun. 2017. Vol. 8. No. 1. DOI: 10.1038/ncomms15786

[5] Andrade F, Aldámiz-Echevarría L, Llarena M, Couce ML. Sanfilippo syndrome: Overall review. Pediatr Int. 2015;57(3):331–338. DOI: 10.1111/ped.12636

[6] Andrade F., Aldámiz-Echevarría L., Llarena M., Couce M.L. Sanfilippo syndrome: Overall review // Pediatr. Int. 2015. Vol. 57. No. 3. P. 331–338. DOI: 10.1111/ped.12636

[7] Shimada T, Tomatsu S, Mason RW, et al. Di-sulfated keratan sulfate as a novel biomarker for mucopolysaccharidosis II, IVA, and IVB. JIMD Reports. 2014;21:1–13. DOI: 10.1007/8904_2014_330

[8] Shimada T., Tomatsu S., Mason R.W. et al. Di-sulfated keratan sulfate as a novel biomarker for mucopolysaccharidosis II, IVA, and IVB // JIMD Reports. 2014. Vol. 21. P. 1–13. DOI: 10.1007/8904_2014_330

[9] Tomanin R, Karageorgos L, Zanetti A, et al. Mucopolysaccharidosis type VI (MPS VI) and molecular analysis: Review and classification of published variants in the ARSB gene. Hum Mutat. 2018;39(12):1788–1802. DOI: 10.1002/humu.23613

[10] Tomanin R., Karageorgos L., Zanetti A. et al. Mucopolysaccharidosis type VI (MPS VI) and molecular analysis: Review and classification of published variants in the ARSB gene // Hum. Mutat. 2018. Vol. 39. No. 12. P. 1788–1802. DOI: 10.1002/humu.23613

[11] Natowicz MR, Short MP, Wang Y et al. Clinical and biochemical manifestations of hyaluronidase deficiency. N Engl J Med. 1996;335(14):1029–1033. DOI: 10.1056/nejm199610033351405

[12] Natowicz M.R., Short M.P., Wang Y. et al. Clinical and biochemical manifestations of hyaluronidase deficiency // N. Engl. J. Med. 1996. Vol. 335. No. 14. P. 1029–1033. DOI: 10.1056/nejm199610033351405

[13] Simonaro CM, Haskins ME, Schuchman EH. Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: A possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab Invest. 2001;81(9):1319–1328. DOI: 10.1038/labinvest.3780345

[14] Simonaro C.M., Haskins M.E., Schuchman E.H. Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: A possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses // Lab. Invest. 2001. Vol. 81. No. 9. P. 1319–1328. DOI: 10.1038/labinvest.3780345

[15] Wang JY, Roehrl MH. Glycosaminoglycans are a potential cause of rheumatoid arthritis. Proc Natl Acad Sci USA. 2002;99(22):14362–14367. DOI: 10.1073/pnas.222536599

[16] Wang J.Y., Roehrl M.H. Glycosaminoglycans are a potential cause of rheumatoid arthritis // Proc. Natl. Acad. Sci. USA. 2002. Vol. 99. No. 22. P. 14362–13367. DOI: 10.1073/pnas.222536599

[17] Simonaro CM, D’Angelo M, He X, et al. Mechanism of glycosaminoglycan-mediated bone and joint disease. Am J Pathol. 2008;172(1):112–22. DOI: 10.2353/ajpath.2008.070564

[18] Simonaro C.M., D’Angelo M., He X. et al. Mechanism of glycosaminoglycan-mediated bone and joint disease // Am. J. Pathol. 2008. Vol. 172. No. 1. P. 112–122. DOI: 10.2353/ajpath.2008.070564

[19] Opoka-Winiarska V, Jurecka A, Emeryk A, Tylki-Szymańska A. Osteoimmunology in mucopolysaccharidoses type I, II, VI and VII. Immunological regulation of the osteoarticular system in the course of metabolic inflammation. Osteoarthritis Cartilage. 2013;21(12):1813–1823. DOI: 10.1016/j.joca.2013.08.001

[20] Opoka-Winiarska V., Jurecka A., Emeryk A., Tylki-Szymańska A. Osteoimmunology in mucopolysaccharidoses type I, II, VI and VII. Immunological regulation of the osteoarticular system in the course of metabolic inflammation // Osteoarthritis Cartilage. 2013. Vol. 21. No. 12. P. 1813–1823. DOI: 10.1016/j.joca.2013.08.001

[21] White KK. Orthopaedic aspects of mucopolysaccharidoses. Rheumatol. 2011;50(suppl 5):v26–v33. DOI: 10.1093/rheumatology/ker393

[22] White K.K. Orthopaedic aspects of mucopolysaccharidoses // Rheumatol. 2011. Vol. 50. Suppl. 5. P. v26–v33. DOI: 10.1093/rheumatology/ker393

[23] Borgo A, Cossio A, Gallone D, et al. Orthopaedic challenges for mucopolysaccharidoses. Ital J Pediatr. 2018;44(S2). DOI: 10.1186/s13052-018-0557-y

[24] Borgo A., Cossio A., Gallone D. et al. Orthopaedic challenges for mucopolysaccharidoses // Ital. J. Pediatr. 2018. Vol. 44. No. S2. DOI: 10.1186/s13052-018-0557-y

[25] Tomatsu S, Montaño AM, Nishioka T, Orii T. Mucopolysaccharidosis IV (Morquio Syndrome). Lysosomal Storage Disorders. 2007:433–445. DOI: 10.1007/978-0-387-70909-3_27

[26] Tomatsu S., Montaño A.M., Nishioka T., Orii T. Mucopolysaccharidosis IV (Morquio Syndrome) // Lysosomal Storage Disorders. 2007. P. 433–445. DOI: 10.1007/978-0-387-70909-3_27

[27] Arbisser AI, Donnelly KA, Scott CI, et al. Morquio-like syndrome with beta galactosidase deficiency and normal hexosamine sulfatase activity: Mucopolysaccharidosis IVB. Am J Med Genet. 1977;1(2):195–205. DOI: 10.1002/ajmg.1320010205

[28] Arbisser A.I., Donnelly K.A., Scott C.I. et al. Morquio-like syndrome with beta galactosidase deficiency and normal hexosamine sulfatase activity: Mucopolysaccharidosis IVB // Am. J. Med. Genet. 1977. Vol. 1. No. 2. P. 195–205. DOI: 10.1002/ajmg.1320010205

[29] Bychkov I, Kuznetsova A, Baydakova G, et al. Processed pseudogene insertion in GLB1 causes Morquio B disease by altering intronic splicing regulatory landscape. NPJ genomic medicine. [in print].

[30] Bychkov I., Kuznetsova A., Baydakova G. et al. Processed pseudogene insertion in GLB1 causes Morquio B disease by altering intronic splicing regulatory landscape // NPJ Genom. Med. [in print].

[31] Hunter C. A rare disease in two brothers. Proc R Soc Med. 1917; 10(Study_Dis_Child):104–116. DOI: 10.1177/003591571701001833

[32] Hunter C. A rare disease in two brothers // Proc. R. Soc. Med. 1917. Vol. 10. (Study_Dis_Child). P. 104–116. DOI: 10.1177/003591571701001833

[33] Zhou J, Lin J, Leung WT, Wang L. A basic understanding of mucopolysaccharidosis: Incidence, clinical features, diagnosis, and management. Intractable & Rare Diseases Research. 2020;9(1):1–9. DOI: 10.5582/irdr.2020.01011

[34] Zhou J., Lin J., Leung W.T., Wang L. A basic understanding of mucopolysaccharidosis: Incidence, clinical features, diagnosis, and management // Intractable & Rare Diseases Research. 2020. Vol. 9. No. 1. P. 1–9. DOI: 10.5582/irdr.2020.01011

[35] Lin H-Y, Lin S-P, Chuang C-K, et al. Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004. Am J Med Genet A. 2009;149A(5):960–964. DOI: 10.1002/ajmg.a.32781

[36] Lin H.-Y., Lin S.-P., Chuang C.-K. et al. Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004 // Am. J. Med. Genet. A. 2009. Vol. 149A. No. 5. P. 960–964. DOI: 10.1002/ajmg.a.32781

[37] Chen X, Qiu W, Ye J, et al. Demographic characteristics and distribution of lysosomal storage disorder subtypes in Eastern China. J Hum Genet. 2016;61(4):345–349. DOI: 10.1038/jhg.2015.155

[38] Chen X., Qiu W., Ye J. et al. Demographic characteristics and distribution of lysosomal storage disorder subtypes in Eastern China // J. Hum. Genet. 2016. Vol. 61. No. 4. P. 345–349. DOI: 10.1038/jhg.2015.155

[39] Puckett Y, Bui E, Zelicoff A, Montano A. Epidemiology of mucopolysaccharidoses (MPS) in the United States: challenges and opportunities. Mol Genet Metab. 2017;120(1−2):S111. DOI: 10.1016/j.ymgme.2016.11.285

[40] Puckett Y., Bui E., Zelicoff A., Montano A. Epidemiology of mucopolysaccharidoses (MPS) in the United States: challenges and opportunities // Mol. Genet. Metab. 2017. Vol. 120. No. 1−2. P. S111. DOI: 10.1016/j.ymgme.2016.11.285

[41] Lowry RB, Applegarth DA, Toone JR, et al. An update on the frequency of mucopolysaccharide syndromes in British Columbia. Hum Genet. 1990;85(3). DOI: 10.1007/bf00206770

[42] Lowry R.B., Applegarth D.A., Toone J.R. et al. An update on the frequency of mucopolysaccharide syndromes in British Columbia // Hum. Genet. 1990. Vol. 85. No. 3. DOI: 10.1007/bf00206770

[43] Silveira M, Buriti A, Martins A, et al. Audiometric evaluation in individuals with mucopolysaccharidosis. Clinics. 2018;73. DOI: 10.6061/clinics/2018/e523

[44] Silveira M., Buriti A., Martins A. et al. Audiometric evaluation in individuals with mucopolysaccharidosis // Clinics. 2018. Vol. 73. DOI: 10.6061/clinics/2018/e523

[45] Keilmann A, Nakarat T, Bruce IA, et al. Hearing loss in patients with mucopolysaccharidosis II: Data from HOS – the Hunter Outcome Survey. J Inherit Metab Dis. 2011;35(2):343–353. DOI: 10.1007/s10545-011-9378-5

[46] Keilmann A., Nakarat T., Bruce I.A. et al. Hearing loss in patients with mucopolysaccharidosis II: Data from HOS – the Hunter Outcome Survey // J. Inherit. Metab. Dis. 2011. Vol. 35. No. 2. P. 343–353. DOI: 10.1007/s10545-011-9378-5

[47] Valstar MJ, Bertoli-Avella AM, Wessels MW, et al. Mucopolysaccharidosis type IIID: 12 new patients and 15 novel mutations. Hum Mutat. 2010;31(5):е1348−1360. DOI: 10.1002/humu.21234

[48] Valstar M.J., Bertoli-Avella A.M., Wessels M.W. et al. Mucopolysaccharidosis type IIID: 12 new patients and 15 novel mutations // Hum. Mutat. 2010. Vol. 31. No. 5. P. е1348−1360. DOI: 10.1002/humu.21234

[49] Jansen ACM, Cao H, Kaplan P, et al. Sanfilippo syndrome type D. Archiv Neurology. 2007;64(11):1629. DOI: 10.1001/archneur.64.11.1629

[50] Jansen A.C.M., Cao H., Kaplan P., et al. Sanfilippo syndrome type D // Archiv. Neurology. 2007. Vol. 64. No. 11. P. 1629. DOI: 10.1001/archneur.64.11.1629

[51] Zafeiriou DI, Savvopoulou-Augoustidou PA, Sewell A, et al. Serial magnetic resonance imaging findings in mucopolysaccharidosis IIIB (Sanfilippo’s syndrome B). Brain Dev. 2001;23:385–389. DOI: 10.1016/s0387-7604(01)00242-x

[52] Zafeiriou D.I., Savvopoulou-Augoustidou P.A., Sewell A. et al. Serial magnetic resonance imaging findings in mucopolysaccharidosis IIIB (Sanfilippo’s syndrome B) // Brain Dev. 2001. Vol. 23. P. 385–389. DOI: 10.1016/s0387-7604(01)00242-x

[53] Lin H-Y, Shih S-C, Chuang C-K, et al. Assessment of hearing loss by pure-tone audiometry in patients with mucopolysaccharidoses. Mol Genet Metabol. 2014;111(4):533–538. DOI: 10.1016/j.ymgme.2014.02.003

[54] Lin H.-Y., Shih S.-C., Chuang C.-K. et al. Assessment of hearing loss by pure-tone audiometry in patients with mucopolysaccharidoses // Mol. Genet. Metab. 2014. Vol. 111. No. 4. P. 533–538. DOI: 10.1016/j.ymgme.2014.02.003

[55] Nagao K, Morlet T, Haley E, et al. Neurophysiology of hearing in patients with mucopolysaccharidosis type IV. Mol Genet Metabol. 2018;123(4):472–478. DOI: 10.1016/j.ymgme.2018.02.002

[56] Nagao K., Morlet T., Haley E. et al. Neurophysiology of hearing in patients with mucopolysaccharidosis type IV // Mol. Genet. Metab. 2018. Vol. 123. No. 4. P. 472–478. DOI: 10.1016/j.ymgme.2018.02.002

[57] Riedner ED, Levin LS. Hearing patterns in Morquio’s syndrome (mucopolysaccharidosis IV). Arch Otolaryngol. 1977;103:518–520. DOI: 10.1001/archotol.1977.00780260048003

[58] Riedner E.D., Levin L.S. Hearing patterns in Morquio’s syndrome (mucopolysaccharidosis IV) // Arch. Otolaryngol. 1977. Vol. 103. P. 518–520. DOI: 10.1001/archotol.1977.00780260048003

[59] Akyol MU, Alden TD, Amartino H, et al. Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance. Orphan J Rare Dis. 2019;14(1). DOI: 10.1186/s13023-019-1080-y

[60] Akyol M.U., Alden T.D., Amartino H. et al. Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance // Orphan. J. Rare Dis. 2019. Vol. 14. No. 1. DOI: 10.1186/s13023-019-1080-y

[61] Montaño AM, Lock-Hock N, Steiner RD, et al. Clinical course of sly syndrome (mucopolysaccharidosis type VII). J Med Genet. BMJ. 2016;53(6):403–418. DOI: 10.1136/jmedgenet-2015-103322

[62] Montaño A.M., Lock-Hock N., Steiner R.D. et al. Clinical course of sly syndrome (mucopolysaccharidosis type VII) // BMJ. 2016. Vol. 53. No. 6. P. 403–418. DOI: 10.1136/jmedgenet-2015-103322

[63] Imundo L, LeDuc CA, Guha S, et al. A complete deficiency of Hyaluronoglucosaminidase 1 (HYAL1) presenting as familial juvenile idiopathic arthritis. J Inher Metab Dis. 2011;34(5):1013–1022. DOI: 10.1007/s10545-011-9343-3

[64] Imundo L., LeDuc C.A., Guha S. et al. A complete deficiency of Hyaluronoglucosaminidase 1 (HYAL1) presenting as familial juvenile idiopathic arthritis // J. Inherit. Metab. Dis. 2011. Vol. 34. No. 5. P. 1013–1022. DOI: 10.1007/s10545-011-9343-3

[65] Van den Eeden YNT, Unter Ecker N, Kleinertz H, et al. Total hip arthroplasty in a patient with mucopolysaccharidosis type IVB. Case Rep Orthop. 2021;2021:1–8. DOI: 10.1155/2021/5584408

[66] Van den Eeden Y.N.T., Unter Ecker N., Kleinertz H. et al. Total hip arthroplasty in a patient with mucopolysaccharidosis type IVB // Case Rep. Orthop. 2021. Vol. 2021. P. 1–8. DOI: 10.1155/2021/5584408

RIGHTS & PERMISSIONS

Kenis V.M., Gorobets L.V., Dimitrieva A.Y., Zhmurova-Kriventsova A.A., Bychkov I.O., Baydakova G.V., Markova T.V., Zakharova E.Y.